Jenny C. Chang, MD

Emily Herrmann Chair in Cancer Research & Director, Cancer Center
Professor of Cancer, Institute for Academic Medicine
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Dr. Jenny C. Chang is the Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Texas. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, which has led to several publications and international presentations. Dr. Chang’s clinical research aims to evaluate novel biologic agents in breast cancer patients.

Description of Research

Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.

Areas Of Expertise

Cancer Stem cells Breast cancer High throughput
Education & Training

, University of Cambridge
, University of London

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods
Patel, TA, Puppala, M, Ogunti, RO, Ensor, Jr. JE, He, T, Shewale, JB, Ankerst, DP, Kaklamani, VG, Rodriguez, AA, Wong, STC & Chang, JC 2016, Cancer. DOI:

HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells
Sadik, H, Korangath, P, Nguyen, NK, Gyorffy, B, Kumar, R, Hedayati, M, Teo, WW, Park, S, Panday, H, Munoz, TG, Menyhart, O, Shah, N, Pandita, RK, Chang, JC, DeWeese, T, Chang, HY, Pandita, TK & Sukumar, S 2016, Cancer Research, vol 76, no. 15, pp. 4443-4456. DOI:

Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion
Mazumdar, A, Poage, GM, Shepherd, J, Tsimelzon, A, Hartman, ZC, Den Hollander, P, Hill, J, Zhang, Y, Chang, J, Hilsenbeck, SG, Fuqua, S, Kent Osborne, C, Mills, GB & Brown, PH 2016, Breast Cancer Research and Treatment, pp. 1-14. DOI:

The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair
Liang, DH, Choi, DS, Ensor, JE, Kaipparettu, BA, Bass, BL & Chang, JC 2016, Cancer Letters, vol 376, no. 2, pp. 249-258. DOI:

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: Results from a phase Ib/IIa study
Martin, M, Fumoleau, P, Dewar, JA, Albanell, J, Limentani, SA, Campone, M, Chang, JC, Patre, M, Strasak, A, de Haas, SL, Xu, J & Garcia-Saenz, JA 2016, Annals of Oncology, vol 27, no. 7, mdw157, pp. 1249-1256. DOI:

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
Balko, JM, Schwarz, LJ, Luo, N, Estrada, MV, Giltnane, JM, Dávila-González, D, Wang, K, Sánchez, V, Dean, PT, Combs, SE, Hicks, D, Pinto, JA, Landis, MD, Doimi, FD, Yelensky, R, Miller, VA, Stephens, PJ, Rimm, DL, Gómez, H, Chang, JC, Sanders, ME, Cook, RS & Arteaga, CL 2016, Science Translational Medicine, vol 8, no. 334, 334ra53. DOI:

Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival
Hollander, PD, Rawls, K, Tsimelzon, A, Shepherd, J, Mazumdar, A, Hill, J, Fuqua, SAW, Chang, JC, Osborne, CK, Hilsenbeck, SG, Mills, GB & Brown, PH 2016, Cancer Research, vol 76, no. 7, pp. 1942-1953. DOI:

A comparison between DASL and Affymetrix on probing the whole-transcriptome
Jeong, J, Audet, R, Chang, J, Wong, H, Willis, S, Young, B, Edgerton, S, Thor, A, Sledge, G, Duchnowska, R, Jassem, J, Adamowicz, K, Leyland-Jones, B & Shen, C 2016, Journal of the Korean Statistical Society, vol 45, no. 1, pp. 149-155. DOI:

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
Tanei, T, Choi, DS, Rodriguez, AA, Liang, DH, Dobrolecki, L, Ghosh, M, Landis, MD & Chang, JC 2016, Breast Cancer Research, vol 18, no. 1, 6. DOI:

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Liang, DH, Ensor, JE, Liu, ZB, Patel, A, Patel, TA, Chang, JC & Rodriguez, AA 2016, Breast Cancer Research and Treatment, vol 155, no. 1, pp. 139-149. DOI:

Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, JC 2016, Medicine (United States), vol 95, no. 1, pp. S20-S25. DOI:

Therapeutic targeting of casein kinase 1d in breast cancer
Rosenberg, LH, Lafitte, M, Quereda, V, Grant, W, Chen, W, Bibian, M, Noguchi, Y, Fallahi, M, Yang, C, Chang, JC, Roush, WR, Cleveland, JL & Duckett, DR 2015, Science Translational Medicine, vol 7, no. 318, 318ra202. DOI:

Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy
Giuliano, M, Hu, H, Wang, YC, Fu, X, Nardone, A, Herrera, S, Mao, S, Contreras, A, Gutierrez, C, Wang, T, Hilsenbeck, SG, Angelis, CD, Wang, NJ, Heiser, LM, Gray, JW, Lopez-Tarruella, S, Pavlick, AC, Trivedi, MV, Chamness, GC, Chang, JC, Osborne, CK, Rimawi, MF & Schiff, R 2015, Clinical Cancer Research, vol 21, no. 17, pp. 3995-4003. DOI:

Activating PIK3CA mutations induce an epidermal growth factor receptor (EGFR)/extracellular signal-regulated Kinase (ERK) paracrine signaling axis in basal-like breast cancer
Young, CD, Zimmerman, LJ, Hoshino, D, Formisano, L, Hanker, AB, Gatza, ML, Morrison, MM, Moore, PD, Whitwell, CA, Dave, B, Stricker, T, Bhola, NE, Silva, GO, Patel, P, Brantley-Sieders, DM, Levin, M, Horiates, M, Palma, NA, Wang, K, Stephens, PJ, Perou, CM, Weaver, AM, OShaughnessy, JA, Chang, JC, Park, BH, Liebler, DC, Cook, RS & Arteaga, CL 2015, Molecular and Cellular Proteomics, vol 14, no. 7, pp. 1959-1976. DOI:

Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer
Crew, KD, Ho, KA, Brown, P, Greenlee, H, Bevers, TB, Arun, B, Sneige, N, Hudis, C, Mcarthur, HL, Chang, J, Rimawi, M, Cornelison, TL, Cardelli, J, Santella, RM, Wang, A, Lippman, SM & Hershman, DL 2015, Journal of Human Nutrition and Dietetics, vol 28, no. 3, pp. 272-282. DOI:

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer
Burstein, MD, Tsimelzon, A, Poage, GM, Covington, KR, Contreras, A, Fuqua, SAW, Savage, MI, Osborne, CK, Hilsenbeck, SG, Chang, JC, Mills, GB, Lau, CC & Brown, PH 2015, Clinical Cancer Research, vol 21, no. 7, pp. 1688-1698. DOI:

Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer
Bharadwaj, U, Eckols, TK, Kolosov, M, Kasembeli, MM, Adam, A, Torres, D, Zhang, X, Dobrolecki, LE, Wei, W, Lewis, MT, Dave, B, Chang, JC, Landis, MD, Creighton, CJ, Mancini, MA & Tweardy, DJ 2015, Oncogene, vol 34, no. 11, pp. 1341-1353. DOI:

Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer
Granados-Principal, S, Liu, Y, Guevara, ML, Blanco, E, Choi, DS, Qian, W, Patel, T, Rodriguez, AA, Cusimano, J, Weiss, HL, Zhao, H, Landis, MD, Dave, B, Gross, SS & Chang, JC 2015, Breast Cancer Research, vol 17, no. 1, 25. DOI:

The Role of Combined Radiation and Immunotherapy in Breast Cancer Treatment
Farach, A, Farach-Carson, M, Butler, EB, Chang, JC & Teh, B 2015, Journal of Radiation Oncology, vol 347, pp. 347-354.

Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition
Zhu, X, Zhong, J, Zhao, Z, Sheng, J, Wang, J, Liu, J, Cui, K, Chang, J, Zhao, H & Wong, S 2015, Oncotarget, vol 6, no. 28, pp. 25320-25338. DOI: